Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug formulation
Biotech
Pharvaris oral hereditary angioedema med cuts attacks in phase 2
Patients taking Pharvaris’ preventative oral medicine for hereditary angioedema had an 84.5% reduction in monthly attacks during a phase 2 study.
Annalee Armstrong
Dec 6, 2023 10:18am
Astellas taps ReForm to improve clinical-phase biologics
Mar 5, 2019 9:39am
After nearly 3 years, FDA lifts hold on Aptose cancer drug
Jun 29, 2018 9:05am
Argenx boosts pipeline with new version of lead drug
Jun 14, 2018 10:50am
Former Pfizer exec invests in $10M for cancer startup
Jun 28, 2016 9:43am
